Sort
30,917 grants matching “tumor microenvironment”
DCE MRI Study for Breast Cancer.
$520,846Sungheon Gene Kim · New York University School Of Medicine · R01 · FY2013 · CA
Non-invasive Quantification of Dose-Exposure-Response of PD-L1 Therapeutics at the Tumor
$520,780Sridhar Nimmagadda · Johns Hopkins University · R01 · FY2018 · CA
Localized immunotherapy using alum-binding therapeutics
$520,695Darrell J Irvine · Massachusetts Institute Of Technology · R01 · FY2022 · EB
Tumor microenvironment: Impact on T cell tumor-targeting, activation and survival
$520,680Ronald G Blasberg · Sloan-Kettering Inst Can Research · R01 · FY2012 · CA
Identifying and exploiting therapeutic vulnerabilities of tumor-host interactions that drive bone-to-meninges breast cancer metastasis
$520,653Dorothy A Sipkins · Duke University · R01 · FY2025 · CA
Hydrogel-based Organoids of African-American Lymphomas to Study B Cell Receptor Pathway Inhibitors
$520,646Ankur Singh · Georgia Institute Of Technology · R01 · FY2024 · CA
Metabolic Regulation ofPD-L1 in CD11c+ Cells
$520,593Cong Yan · Indiana University Indianapolis · R01 · FY2023 · CA
Metabolic Regulation ofPD-L1 in CD11c+ Cells
$520,593Cong Yan · Indiana University Indianapolis · R01 · FY2022 · CA
Developing new therapeutic strategies for brain metastasis
$520,544Eva Hernando · New York University School Of Medicine · R01 · FY2024 · CA
Role of metalloproteinases in mammary gland remodeling
$520,530Zena Werb · University Of California, San Francisco · R01 · FY2011 · CA
Artemin overexpression in oral cancer pain and carcinogenesis
$520,500Donna G Albertson · New York University · R01 · FY2020 · CA
EPHA2 Receptor Signaling in Breast Cancer Mechanotransduction
$520,482Elena B Pasquale · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2023 · CA
Defining bone ecosystem effects on metastatic prostate cancer evolution and treatment response using an integrated mathematical modeling approach
$520,437Conor C Lynch · H. Lee Moffitt Cancer Ctr & Res Inst · U01 · FY2020 · CA
IL-17-driven mechanisms for tumor progression and resistance to therapies
$520,309Xiaoxia Li · Cleveland Clinic Lerner Com-Cwru · P01 · FY2022 · CA
IL-17-driven mechanisms for tumor progression and resistance to therapies
$520,309Thaddeus S Stappenbeck · Cleveland Clinic Lerner Com-Cwru · P01 · FY2025 · CA
Administrative Core
$520,261Mauro Ferrari · Methodist Hospital Research Institute · U54 · FY2016 · CA
Targeted Therapy for Lymphoid Malignancies
$520,184John C Byrd · Ohio State University · R01 · FY2014 · CA
Evaluation of treatment predictors reflecting beta-catenin activation in hepatocellular carcinoma
$520,008Sandi Alexander Kwee · Queen'S Medical Center · R01 · FY2021 · CA
Tissue-Engineered Models of Glioblastoma for Evaluating Treatment Response
$519,881Stephanie Kristin Seidlits · University Of Texas At Austin · R01 · FY2022 · CA
Loss of NF1 drives hormone dependent mammary carcinogenesis in a rat model with intact immune system
$519,825Deeann Wallis-Schultz · University Of Alabama At Birmingham · R01 · FY2024 · CA
Role of inflammation, innate resistance, and immunity in carcinogenesis
$519,797Giorgio Trinchieri · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Identifying and exploiting therapeutic vulnerabilities of tumor-host interactions that drive bone-to-meninges breast cancer metastasis
$519,766Dorothy A Sipkins · Duke University · R01 · FY2023 · CA
Targeting the Microenvironment/Oncogene Cooperation to treat poor prognosis T-ALL
$519,672Nadia Carlesso · Beckman Research Institute/City Of Hope · R01 · FY2025 · CA
Targeting tumor-associated macrophages for triple-negative breast cancer treatment
$519,592Mingye Feng · Beckman Research Institute/City Of Hope · R01 · FY2025 · CA
STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma
$519,464Jinming Gao · Ut Southwestern Medical Center · U01 · FY2019 · CA